News

In an interview during the 2024 AAAAI conference, Casale addressed his team’s findings regarding epinephrine nasal spray and its effectiveness with regard to exacerbations of urticaria.

The approval was based on clinical data from 3 multicenter, randomized trials which demonstrated the safety, efficacy, and biosimilarity of adalimumab-ryvk compared with the reference product.

A new study found female teens and young adults were more likely to have an increased antidepressant dispensing rate during the pandemic than male peers.

Cross-sectional survey results suggest most providers are recommending HCV screening based on patient risk factors rather than universally for all patients 18-79 years of age.

These findings may allow for patients with severe allergic reactions to have an alternative to epinephrine auto-injector devices.

Survodutide, a dual agonist from Boehringer Ingelheim and Zealand Pharma, was associated with MASH resolution without worsening fibrosis among 83% of participants in a phase 2 trial.

NAFLD, ALD, liver fibrosis and cirrhosis, and recently diagnosed viral hepatitis were all associated with a greater risk of cataract.

Robert Wood, MD, principal investigator of the OUtMATCH trial, offers insight into the trial and its results beyond the primary outcome, with a focus on what it means for patients and providers.

More than half of older patients admitted to geriatric units in France had iron deficiency, including patients without anemia.

In this interview, Ebisawa discusses his team’s recent research into the frequently-discussed non-injector epinephrine alternative neffy.

A new study found a greater sleep apnea risk was linked to verbal episodic memory decline and worse sleep quality was linked to executive function decline.

Rilzabrutinib, an oral BTK inhibitor, demonstrates efficacy in reducing itch and disease activity among patients with chronic spontaneous urticaria in phase 2 dose-ranging trial at AAAAI 2024.

Dubinsky discusses findings from a post-hoc analysis of the head-to-head SEQUENCE trial of risankizumab versus ustekinumab in patients with Crohn disease refractory to anti-TNF therapy.

A large language model demonstrated comparative diagnostic accuracy and completeness in glaucoma and retina disease to fellowship-trained ophthalmologists.

Of those who received an infliximab biosimilar, 87.8% were maintained on a single biosimilar without the need to switch to an alternative product.

Worse examination-based and self-reported vision impairment was associated with depressive and anxiety symptoms among adults aged ≥65 years.

These findings, to be presented at AAAAI, may help to expand upon clinicians’ awareness of the mechanics of air pollution’s effect on asthma.

The MANDARA trial results, published in NEJM, show benralizumab's noninferiority to mepolizumab in eosinophilic granulomatosis with polyangiitis, with potential for oral glucocorticoid discontinuation.

The FDA’s decision is planned for June 2024, and follows the successful results of the BOREAS and NOTUS trials.

A new study found patients with Parkinson’s disease have a lower daytime light exposure with a mean light intensity of 201.1 lux than controls with a light intensity of 337.7 lux.

All patients who received an HCV+ organ achieved SVR12 and had lower rates of rejection and chronic lung allograft dysfunction compared to uninfected donor organ recipients.

This analysis, to be presented at AAAAI, suggests that adolescents’ attendance of daycare may lead to decreased IgE levels and diminished food and aeroallergen sensitization rates.

A new study found gender inequality, poor work-life balance, a lack of workplace autonomy, and caregiving responsibilities contribute to women in healthcare professions having more stress than their male colleagues.

Zhang discusses the consequences of stigmatizing language for substance use disorders and reasons gastroenterologists and hepatologists may be falling behind.

Robert Wood, MD, discusses how the FDA approval of omalizumab (Xolair) changes the management of pediatric food allergy and what type of hurdles to optimal uptake the community may encounter.

This analysis suggests that the financial burden of oral food challenges may be offset slightly through the use of FPIES.

Rusfertide maintained a hematocrit of <45% and reduced or eliminated the use of phlebotomy in patients with polycythemia vera.

Results from the phase 3 trial showed seladelpar elicited biochemical response, normalized alkaline phosphatase, and reduced pruritus at a greater rate than placebo.